By Market Intelligence Team

Better Therapeutics, Inc., a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, announced that the U.S. Patent and Trade Office (USPTO) has granted a patent for a number of key features core to the company’s prescription digital therapeutics platform. The platform is designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT. The patent protects the technology through at least September 2039. The patent was granted on June 7, 2022, as U.S. Patent No. 11,355,228. It covers methods and apparatus for generating and…
Content Restricted

You must be a Free or Elite member to view this resource.

Log In | Sign up or learn more about membership options.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!